Novo Nordisk India partners with Emcure Pharma to distribute and market Poviztra (semaglutide) nationwide, expanding access ...

Emcure Pharma becomes the first Indian company to hold exclusive rights to distribute and commercialise Poviztra, a ...

Novo Nordisk India and Emcure Pharma announced a strategic partnership on Monday to launch Poviztra (semaglutide injection ...

Medicare will cover GLP-1 weight loss drugs for specific patient groups, beginning in mid-2026, under a deal struck with drugmakers.

There’s plenty to like about the lower direct-to-consumer prices the White House negotiated with Eli Lilly and Novo Nordisk. There are also caveats and some unanswered questions.

After [losing out to Pfizer]( ...

Oral GLP-1 weight loss pills could replace injections by March 2026 at $150 monthly, Medicare chief Dr. Mehmet Oz predicted ...

The results were published in The New England Journal of Medicine as part of the OASIS 4 phase 3 trial. The findings show ...

Novo Nordisk India and Emcure Pharma are partnering to introduce Poviztra, a weight-loss medication based on semaglutide, in India. This collaboration aims to enhance accessibility and distribution of ...

Novo Nordisk has partnered with India's Emcure Pharmaceuticals to exclusively distribute and market its weight-loss drug ...

This article was reviewed by Lynn Marie Morski, MD, JD. Does Ozempic® Cause Bone Loss? Key takeaways: Taking Ozempic® may ...

Eli Lilly's Mounjaro and Zepbound deliver accelerated weight loss rates compared to Novo Nordisk's Wegovy. Learn why LLY ...